Orhub’s Ryan Fernan Becomes Head Of Pur Biologics, Leading Regenerative Therapeutic Efforts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Stifel Reiterates Buy Rating on Baxter International (BAX)
July 28, 2022 9:57 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $75.00 price target on Baxter International (NYSE: BAX)
The analyst comments "Macro challenges have been very much in evidence during initial 2Q22 MedTech reports. In Baxters 2Q, we are seeing the most significant negative... More
Evercore ISI on Baxter International (BAX) Guidance Update: 'we think the magnitude of the cut was a surprise'
July 28, 2022 9:55 AM EDTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $80.00 price target on Baxter International (NYSE: BAX).
The analyst comments "BAX reported organic rev growth of ~3%, which came in ~1% below Guide expectations. Total revs of $3.74 Bn came 3% below ST, and incl Fx impact of -500 bps (we are unsure... More
KeyBanc on Baxter International (BAX), Believes Investors are 'Dissappointed' With Q2 2022 Earnings Report and Guidance Update
July 28, 2022 9:53 AM EDTKeyBanc analyst Matthew Mishan reiterated an Overweight rating and $87.00 price target on Baxter International (NYSE: BAX).
The analyst comments "We believe investors will view BAXs 2Q22 release and updated 2022 guidance as disappointing. 2Q revenue missed mostly on FX and weaker... More
